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Transrectal ultrasound (TRUS) biopsy can miss 20–30% of clinically significant cancers.
We evaluate an alternative approach—transperineal template-guided mapping biopsy (TTMB) in
the initial and repeat biopsy setting. From January 2005 through September 2008, 373 consecutive
men underwent TTMB (294 men with X1 prior negative biopsy and 79 men as the initial biopsy).
The location of each positive biopsy core, number of positive cores, and percent involvement of
each core was recorded. Cancer detection rate for the initial biopsy was 75.9%. For men with 1, 2,
and X3 prior negative biopsies detection rates were 55.5%, 41.7%, and 34.4%, respectively. In all,
55.5% of the cancers identified were Gleason X7. The majority of the cancers were multifocal.
There was no significant change in the number of positive cores or Gleason score as the number
of prior biopsies increased. The anterior and apical aspects of the prostate were among the most
common cancer locations. TTMB provides a high rate of cancer detection as initial and repeat
biopsy. TTMB was particularly effective at diagnosing anterior and apical cancer. TTMB may have
particular application for men considering active surveillance, with prior negative TRUS biopsies,
and those considering subtotal gland or other minimally invasive treatments.
Prostate Cancer and Prostatic Diseases (2010) 13, 71–77; doi:10.1038/pcan.2009.42; published online 29 September 2009
Keywords: biopsy; mapping biopsy; Gleason score
Introduction
Transrectal ultrasound (TRUS)-guided biopsy using a
12-core scheme is the standard biopsy approach for men
with suspected prostate cancer. Among the benefits of
TRUS-guided biopsy is its fairly good sensitivity, its
ability to be performed during a clinic visit, and the lack
of significant morbidity associated with the procedure.
TRUS biopsy—particularly with the 12-core ap-
proach—provides a reasonable sampling of the prostate
gland. Nonetheless, a significant minority of men with
an initial negative biopsy are found to have prostate
cancer on subsequent biopsies.
1,2 In addition, initial
biopsy pathology frequently underestimates the Gleason
score that would be assigned based on full gland
evaluation.
3 In an effort to reduce false-negative rates
and improve accuracy of staging, investigators have
explored alternative biopsy approaches, including in-
creasing the number of cores sampled and changing
access with a transperineal approach.
Transperineal biopsy, particularly when performed
with a standardized template, provides reliable access
to the entire prostate gland. Also, because template-
based transperineal biopsies are conducted under gen-
eral or regional anesthesia, a larger number of cores are
typically obtained. We report our experience with
transperineal template-guided prostate mapping biopsy
(TTMB) as initial biopsy and in the setting of repeat
biopsy. We focus on rate of cancer detection, relative
portion of potentially insignificant cancers identified,
and location of new cancers identified.
Materials and methods
From January 2005 through September 2008, 373 con-
secutive men underwent TTMB by means of an
anatomic-based technique with sampling of 24 prostate
regions. TTMB was originally used at our institution only
for men who had undergone at least one prior negative
biopsy, but had persistently elevated prostate specific
antigen (PSA) and/or a diagnosis of atypical small acinar
proliferation or multifocal high-grade prostatic intrae-
pithelial neoplasia on prior biopsy. Eventually, as other
institutions began publishing on use of the transperineal
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4,5 we began to offer TTMB to
men as initial biopsy procedure for an elevated PSA. This
study reports on 294 men who underwent TTMB as
repeat biopsy and 79 men who had TTMB performed as
initial biopsy.
The TTMB technique has been described in detail
earlier.
6 All biopsies were performed by a single operator
(GM). Two days before the procedure, Tamsulosin
(0.8mg daily) was initiated and was continued for 2
weeks. TTMB was performed in the operating room
using general anesthesia. All patients received perio-
perative antibiotics. The setup was the same as used for
brachytherapy, with patients in the dorsal lithotomy
position. The prostate was scanned from the level of
the proximal seminal vesicles/base of the prostate to
the apex using the 5.0–7.5MHz transducer (Sonoline;
Seimens Inc., Issaquah, WA, USA). A volumetric ultra-
sonographic evaluation was obtained to estimate pros-
tate size. In addition, the prostate gland and transition
zone (TZ) volumes were estimated as an ellipsoid with
the formula Length Width Height 0.5236.
Transperineal biopsies were obtained through tem-
plate apertures corresponding with the 24 regional
biopsy locations. For each of the 24 regions, one to three
biopsy cores was taken, depending on prostate size. The
18 gauge, 25cm long Max-Core biopsy needles (C.R.
Bard Inc., Covington, GA, USA) were used. For each
biopsy core, the template coordinate and the offset from
base were recorded. Biopsy regions included posterior
prostate (3, 4, 12, 13, 21, 22), posterior lateral (2, 5, 11, 14,
20, 23), anterior lateral (1, 6, 9, 10, 15, 16), anterior apex
(19, 24), and TZ (7, 8, 17, 18) After completion of all
sampling, patients underwent cystoscopic evaluation.
For each patient, the location of each positive biopsy
core, the number of positive cores, and the percent
involvement of each core was recorded. All pathologic
review was performed at the same facility by an expert
prostate pathologist (EA). Only patients with Gleason
score X6 were included as having been diagnosed with
prostate cancer. Of the patients with Gleason 6 cancer, we
wanted to separate out those with potentially insignif-
icant disease—for whom watchful waiting would likely
be the preferred option—from men with disease that
would more seriously merit consideration of definitive
treatment. Investigators at Johns Hopkins
7 have shown
that men who on presurgical saturation biopsy had no
cores of Gleason 46, no core with 450% involvement,
PSA density o0.15, and fewer than three cores involved
were very unlikely to have clinically significant disease
on pathologic review after radical prostatectomy. Clini-
cally insignificant disease for their purposes was defined
as pathologic review of prostatectomy specimen with
tumor o0.5cm
3, organ confined, seminal vesicles and
lymph nodes negative for tumor, and no Gleason pattern
4 or 5. We used the same biopsy criteria as in that study
to identify men with potentially insignificant disease.
One-way analysis of variance and two-sided Fisher
exact test were used to determine the significance of
differences between men undergoing initial versus
repeat biopsies concerning clinical parameters and
TTMB parameters. All data were analyzed with the use
of Statistical Package for Social Sciences, version 14.0
(SPPS Inc., Chicago, IL, USA). Statistical significance was
set at Pp0.005.
Results
Table 1 summarizes the clinical parameters of the study
population, subdivided by the number of prior biopsies.
Table 1 Clinical parameters of the study population
Continuous variable Number of biopsy sessions
1( n¼79) 2 (n¼146) 3 (n¼84) X4( n¼64) P Total (n¼373)
Mean Median Mean Median Mean Median Mean Median Mean Median
Age at biopsy 62.7 63.9 63.0 62.5 64.1 64.0 66.4 66.5 0.011 63.8 64.2
Prebiopsy PSA 5.6 4.8 7.0 5.4 9.1 8.6 13.6 9.3 o0.001 8.3 6.3
Body mass index 28.5 28.0 29.0 27.8 28.3 27.8 28.6 28.1 0.767 28.7 27.9
No. of prior biopsy cores — — 13.7 12.0 25.3 20.0 37.9 30.5 o0.001 22.3 12.0
Categorical variables Count (%) Count (%) Count (%) Count (%) P Count (%)
Prebiopsy TURP 1 (1.3) 0 (0) 1 (1.2) 5 (7.8) 0.001 366 (98.1)
Prebiopsy diagnosis
PIN 0 (0) 9 (6.2) 4 (4.8) 5 (7.8) o0.001 18 (4.8)
Elevated PSA 79 (100) 109 (74.7) 62 (73.8) 46 (71.9) 296 (79.4)
ASAP 0 (0) 28 (19.2) 18 (21.4) 13 (20.3) 59 (15.8)
Tobacco
Never 38 (48.1) 72 (49.2) 40 (47.6) 31 (48.4) 0.724 181 (48.5)
Former 31 (39.2) 53 (36.3) 35 (41.7) 29 (45.3) 148 (39.7)
Current 10 (12.7) 21 (14.4) 9 (10.7) 4 (6.3) 44 (11.8)
Hypertension 33 (41.8) 75 (50.3) 34 (40.5) 32 (50.0) 0.377 174 (46.3)
Diabetes 3 (3.8) 24 (16.4) 11 (13.1) 6 (9.4) 0.039 44 (11.8)
Abbreviations: ASAP, atypical small acinar proliferation; PIN, prostatic intraepithelial neoplasia; PSA, prostate specific antigen; TURP, transurethral resection of
the prostate.
Bold indicates statistically significant.
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Prostate Cancer and Prostatic DiseasesMen undergoing repeat biopsies were on average older
and had a higher prebiopsy PSA. Table 2 summarizes
TTMB parameters of the study population. Men under-
going repeat biopsies had significantly larger prostates,
greater TZ volumes, and higher TZ index.
As presented in Figure 1, the cancer detection rate for
men undergoing initial biopsy was 75.9%. For men with
one, two, and three or more prior negative biopsies
detection rates were 55.5%, 41.7%, and 34.4%, respec-
tively. Table 3 details cancer detection variables for the
men in whom cancer was diagnosed. In all, 55.5% of the
cancers identified were Gleason X7, with 14.6% being
Gleason X8. The majority of the cancers were multifocal.
In all, 61.1% of the men diagnosed had X5 positive cores;
and 25.3% had 412 positive cores. There was no
significant change in the number of positive cores or in
Gleason score as the number of prior biopsies increased.
For men undergoing repeat biopsy, cancer detection
rate was 51.6% for men with persistently elevated PSA
(112 of 217 patients), 37.3% for men with atypical small
acinar proliferation (22 of 59 patients), and 22.2% for men
with prostatic intraepithelial neoplasia (4 of 18 patients).
Table 4 displays the number of potentially insignificant
prostate cancers identified by biopsy session. Overall the
rate of potentially insignificant cancers was low (11.1%),
and there was no increase in the number of potentially
insignificant cancers identified as the number of biopsies
increased.
The location in which Gleason X6 prostate cancers
were identified is presented graphically in Figure 2a–c.
The highlighted circles represent prostate regions, which
frequently (410% of the time) were found to be involved
with cancer. Figure 2a is for men undergoing initial
TTMB and shows that all 24 of the regions sampled were
frequent sites of cancer. Figure 2b and c display results
for men with one and two or more prior negative biopsy
who underwent TTMB. As the number of prior biopsies
increased, only the most-anterior aspects of the prostate
continued to harbor Gleason X6 cancers. Table 5 pro-
vides detail on the cancer detection rate for each region.
Discussion
For men undergoing initial biopsy with PSA between
4 and 10ng per 100ml, prostate cancer detection rates are
approximately 40–45% for the standard 12-core TRUS
biopsy.
8,9 Increasing the number of transrectal cores at
initial biopsy does not appear to significantly improve
yield.
10,11 Eichler et al.
8 pooled data from 68 studies and
found a significant improvement in cancer detection
moving from the standard sextant scheme to a 12-core
approach. However, there was no benefit to further
increasing the number of cores taken. Lane et al.
12
recently reported on a cohort of 257 men who underwent
saturation biopsy (median of 24 cores) as initial work up.
Cancer detection rate (43%) and percent of repeat
biopsies in which cancer was identified (24%) were
similar to that of men undergoing initial nonsaturation
biopsy at their institution. This has been taken as further
evidence against saturation biopsy as an initial strategy.
The transperineal approach for initial biopsy does not
necessarily result in improved detection rates. Most
studies exploring this have used a ‘fan technique,’ in
which all biopsies are obtained through a single perineal
skin puncture and no template is used. Although this
technique is easier to perform, it lacks the structure of
template-guided biopsy. Transperineal biopsies per-
formed in this manner show initial cancer detection
rates of approximately 40%,
13 very similar to the
standard TRUS biopsy. The only reasonably large study
4
Table 2 TTMB parameters of the study population
Continuous variable Number of biopsy sessions
1( n¼79) 2 (n¼146 3 (n¼84) X4( n¼64) P Total (n¼373)
Mean Median Mean Median Mean Median Mean Median Mean Median
No. mapping biopsy cores
a 55.1 55.0 54.7 58.0 53.2 58.0 52.1 58.0 0.323 54.0 57.0
Prostate volume
Volumetric 52.7 45.1 61.8 55.4 73.2 62.7 89.5 75.0 o0.001 67.2 58.0
Ellipsoid 46.2 39.8 54.5 49.0 65.6 57.9 78.9 66.8 o0.001 59.4 51.2
TZ volume
Ellipsoid 19.2 15.2 25.4 18.5 34.2 26.8 43.1 32.8 o0.001 29.1 21.2
Prebiopsy PSA 5.6 4.8 7.0 5.4 9.1 8.6 13.6 9.3 o0.001 8.3 6.3
PSAD 0.15 0.11 0.16 0.12 0.17 0.14 0.22 0.14 0.291 0.17 0.12
TZ PSAD 0.42 0.30 0.49 0.29 0.46 0.31 0.53 0.30 0.859 0.48 0.30
TZ index 0.42 0.37 0.41 0.40 0.46 0.48 0.50 0.51 0.017 0.44 0.42
Abbreviations: PSA, prostate specific antigen; PSAD, prostate specific antigen density; TTMB, transperineal template-guided mapping biopsy;
TZ, transition zone.
aMost recent mapping biopsy.
Bold indicates statistically significant.
Figure 1 Cancer detection rate (by biopsy session).
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Prostate Cancer and Prostatic Diseasesusing a template-guided transperineal approach for
initial biopsy in men with PSA from 4 to 10ng per
100ml, reported a cancer detection rate of 49% with an
average of 18 cores sampled.
In men with an earlier negative biopsy, standard TRUS
re-biopsy has a low rate of cancer detection with yields of
10–20% for the second biopsy,
14–16 and below 10% for
subsequent biopsies.
14,16 This has led to increased use for
repeat biopsies of a saturation approach sampling 18 to
50 or more cores. Increasing the number of cores does
appear to increase detection rate in this setting. However,
the cancers diagnosed tend to be smaller and of lower
grade. A recent review of the Cleveland Clinic experi-
ence found a cancer detection rate of 22% in men with an
earlier negative biopsy.
17 But Gleason score, percent posi-
tive cores, maximum core involvement and bilaterality
were significantly lower in cancers found on repeat bio-
psy. Other large transrectal saturation biopsy series
report detection rates of 25–40% in men with earlier nega-
tive biopsies.
11,18–20 However, two-thirds to three-quar-
ters of the cancers identified in these studies were Glea-
son score p6,
18–20 supporting the assertion that repeat
TRUS biopsy is likely to identify lower grade disease.
In our cohort of men undergoing repeat biopsy with
TTMB, we report an overall yield for of 47%. Of the
cancers identified with TTMB, over half were Gleason
X7, and 14% were Gleason 8 or higher. Potentially
insignificant cancers represented only 11% of total. Even
in men with three or more prior negative biopsies, TTMB
continued to find high-grade, high-volume disease.
In these men, cancer detection rate was 34%; 23% of
cancers detected were Gleason 8 or higher; 59% were
Gleason X7; and 27% had X13 cores involved. Poten-
tially insignificant disease represented only 14% of this
heavily presampled cohort. Unlike the reported experi-
ence of men undergoing repeat biopsy with transrectal
approach,
14,17 there was no significant decrease in
Gleason score or volume of disease in men undergoing
repeat biopsy with TTMB.
The cohort of men in our study undergoing initial
biopsy with TTMB is typical of an average risk group
referred for first prostate biopsy. Median age was 63.9;
median PSA was 4.8ng per 100ml; and median prostate
volume was 45 cc. None of the men in this study had an
abnormal digital rectal exam (DRE). Using TTMB, we
report a cancer detection rate of 75.9% on initial biopsy.
This is significantly higher than the 40–45% yield
expected from standard TRUS biopsy in similar risk
men. Of note, 17% of the cancers identified were Gleason
8 or higher, 60% were Gleason X7, and only 12% repre-
sented potentially insignificant disease.
The distribution of cancers identified on initial and
subsequent TTMB biopsies provides some insight as to
why TTMB seems to have a higher cancer detection rate
than other biopsy schemes. For individuals undergoing
initial biopsy with TTMB (Figure 2a), cancer was
identified frequently in all 24 of our designated biopsy
regions. When TTMB was used after one prior negative
biopsy (Figure 2b), cancer continued to be identified
frequently throughout the entire gland, with the excep-
tions of regions 3, 4, 12, 13, and 22. Not surprisingly,
Table 3 Characteristics of cancers detected
Continuous variables Number of biopsy sessions
1( n¼60) 2 (n¼81) 3 (n¼35) X4( n¼22) P Total (n¼198)
Mean Median Mean Median Mean Median Mean Median Mean Median
Number mapping cores 54.2 54.0 55.8 57.0 53.9 58.0 54.5 58.5 0.603 54.8 56.0
Mean % positive biopsies 22.4 13.4 15.9 10.9 15.5 12.5 17.7 6.4 0.256 18.0 12.1
Categorical variables Number of patients with prostate cancer
Count (%) Count (%) Count (%) Count (%) P Count (%)
Gleason score
6 24 (40.0) 38 (46.9) 17 (48.6) 9 (40.9) 0.183 88 (44.4)
7 26 (43.3) 37 (45.7) 10 (28.6) 8 (36.4) 81 (40.9)
8–10 10 (16.7) 6 (7.4) 8 (22.9) 5 (22.7) 29 (14.6)
No. positive cores
1–4 22 (36.7) 28 (34.6) 14 (40) 13 (59.1) 0.643 77 (38.9)
5–12 21 (35.0) 34 (42) 13 (37.1) 3 (13.6) 71 (35.8)
412 17 (28.3) 19 (23.5) 8 (22.9) 6 (27.3) 50 (25.3)
Prebiopsy diagnosis
PIN 0 (0) 3 (3.7) 1 (2.9) 0 (0) 0.002 4 (2.0)
Elevated PSA 60 (100) 65 (80.2) 28 (80.0) 19 (86.4) 172 (86.9)
ASAP 0 (0) 13 (16.0) 6 (17.1) 3 (13.6) 22 (11.1)
Abbreviations: ASAP, atypical small acinar proliferation; PIN, prostatic intraepithelial neoplasia; PSA, prostate specific antigen.
Italic indicates significance test.
Table 4 Clinically insignificant prostate cancer
No. of biopsy sessions No. of insignificant prostate
cancers/total cancers
1 7/60 (11.7%)
2 9/81 (11.1%)
3 3/35 (8.6%)
44 3/22 (13.6%)
Total 22/198 (11.1%)
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Prostate Cancer and Prostatic Diseasesthese are the most posterior regions of the prostate and
are the regions most easily accessed with a transrectal
biopsy.
The above point is more striking when compared
with men for whom TTMB was used after two or
more earlier negative biopsies (Figure 2c). In these men,
the cancer detection rate remained high (38%), but the
only areas in which cancer was frequently identified
were the anterior-most aspects of the gland (regions 1, 8,
7, 9, 17, 18, 19, 24). Presumably, with a large enough
number of transrectal cores taken (mean of 37.9 prior
cores in men with 3 prior biopsies), cancer closer to the
rectum is fairly readily discovered. However, it appears
that disease in the anterior prostate, particularly the
anterior apex, is not consistently sampled through a
transrectal approach.
Our results are favorable when compared with the
limited number of studies that have evaluated a trans-
perineal template technique for similar risk men (median
PSA 10 or less). Furuno et al.
4 report using transperineal
template-guided approach in the initial biopsy setting
and achieved a 49% cancer detection rate using an
average of only 18 cores. In this same study, the group
reported a 26% yield in the repeat biopsy setting, with an
average of 19 cores sampled. Satoh et al.
21 achieved a 22%
yield in men with at least one prior negative biopsy
using a 22-core transperineal template scheme. More
recently, Moran and Braccioforte
22 using a transperineal
template reported a yield for Gleason X6 cancer of 38%
in men with prior biopsies, taking an average of 40 cores.
On the basis of the above, it appears that the higher
yields achieved in this study are related both to the
number of cores taken and to the greater, structured
access provided with a transperineal template.
As few of these patients went on to prostatectomy,
we do not have whole-mount pathologic data to confirm
Gleason score, tumor location, and clinical significance.
However, our results are in concordance with the results
from large prostatectomy series in which whole-mount
pathologic evaluation of all cancer foci was available. In
particular, our finding on TTMB of high prevalence of
periurethral and TZ foci of disease is consistent with
prior reports. For instance, Leibovich et al.
23 after careful
evaluation of 350 consecutive prostatectomy specimens
found that 84% of patients had disease within 5mm of
the urethra. Chen et al.
24 examined 180 prostatectomy
specimens and found that 54% of patients had foci of
disease in the TZ. The location of cancer foci we report is
not unexpected. What is notable from this study is the
extent to which traditional TRUS biopsy appears to miss
a significant portion of periurethral and anterior/apical
disease.
Figure 2 (a) Initial biopsy: regions with frequent (410% of men) cancer involvement. (b) One prior negative biopsy: regions with frequent
(410% of men) cancer involvement. (c) Two or more prior negative biopsies: regions with frequent (410% of men) cancer involvement.
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In men who go on to prostatectomy after initial standard
TRUS biopsy, studies have found that biopsy Gleason
score is upgraded from 30% to 50% of the time based on
evaluation of the entire prostatectomy specimen.
3 The
prospect of undergrading particularly affects men who
are considering a course of close observation for
suspected minimal disease identified on biopsy. Epstein
et al.
7 evaluated prostatectomy specimens of 103 men
believed to have insignificant cancer based on an initial
TRUS biopsy. They found that 29% of the men had
higher-volume and/or higher-grade disease than expec-
ted after review of prostatectomy specimens. A negative
TTMB may provide reassurance needed to allow men
with an initial diagnosis of minimal disease to pursue a
course of close observation. As well, a subset of men
thought to have insignificant disease may be diagnosed
with more aggressive cancers on TTMB and opt for
definitive treatment.
On another topic, there is significant interest currently
in identifying men who are candidates for focal, rather
than whole gland, definitive treatment for their prostate
cancers.
25 Unfortunately, our existing imaging techno-
logies are not yet able to reliably confirm that a patient
has unifocal disease.
26,27 And magnetic resonance
imaging, the most successful imaging modality to date,
has particular challenges identifying cancers in the
prostate TZ.
26,28 On the basis of our current study and
other published work,
7 even standard TRUS biopsies
probably miss an unacceptably high amount of Gleason
X6 cancer to definitively state a man has unifocal
disease. TTMB—perhaps in conjunction with evolving
imaging technologies—could be used as initial or repeat
biopsy to provide reassurance that a patient is a good
candidate for segmental rather than whole gland treatment.
Limitations
This is a retrospective study that reviews our institu-
tional experience with all men undergoing TTMB from
January 2005 to September 2008. Although cancer
detection yields and proportion of Gleason X7 disease
identified with TTMB is higher than earlier published
reports of TRUS biopsies in similar patient groups; this
report is not a direct, randomized trial that can defini-
tively answer whether TTMB outperforms TRUS biopsy.
Rather, we present this data as hypothesis generating.
TTMB is a more invasive procedure than standard or
saturation TRUS biopsy. Although not the focus of this
study, we have reported earlier morbidity associated
with the procedure.
29 At our institution, TTMB is
associated with a 29% rate of acute urinary retention
and median catheter dependence of one day for men
who required catheterization. In our experience, there
have been no serious complications, no episodes of
sepsis, no impact on erectile function, and no side effects,
which were not self-resolving. Tamsulosin was started
before TTMB and continued for 2 weeks afterwards.
With this prophylaxis, the mean International Prostate
Symptom Score (IPSS) before TTMB was 10.4, and was
4.6 and 3.8 at 7 and 30 days. Post-void residual at
baseline and 30 days was nearly identical (34.4 and
34.3ml).
29 Physicians along with their patients can assess
whether the potentially higher yield from TTMB is worth
the more involved procedure.
No doubt there was an element of self-selection in men
who opted for the more invasive TTMB—particularly for
men undergoing initial biopsy. However, based on PSA
level, age, prostate volume, and lack of abnormal DRE,
our cohort seems fairly representative of a typical group
of men getting initial biopsy. It is not clear that men
willing to undergo TTMB for this study (given the other
comparable demographic factors) would be more likely
to have prostate cancer. However, without a randomized
control arm, we cannot state this definitively.
In addition, TTMB is more expensive than a standard
TRUS biopsy. At our institution, patients were biopsied
under general anesthesia in the operating room (OR).
Additional costs included anesthesiology, operating
suite, and recovery room expenses that would not be
required for an in-office TRUS biopsy. The differences in
cost between TTMB and saturation TRUS biopsy are
likely less, as saturation TRUS biopsies are often
performed under anesthesia.
Finally, even if TTMB has higher yield than standard
or saturation TRUS biopsy, it is not obvious that this
translates into higher definitive cure rates. The fact that
TTMB detection rates remained high after multiple prior
TRUS biopsies and that anterior and apical regions of the
prostate did not appear to be well sampled with TRUS
suggests that at least for some men, their cancer could
have gone undetected for some time without TTMB. This
may have impacted treatment outcomes, or may not
have. To definitively address this issue is well beyond the
scope of this study.
Table 5 Region-specific positive biopsies, stratified by the number
of biopsy sessions
Region Number of biopsy sessions
1 n %2 n (%) 3 n (%) 4+ n (%) All n (%)
Base
1 15 19.0% 23 15.8% 11 13.1% 9 14.1% 58 15.5%
2 16 20.3% 19 13.0% 7 8.3% 5 7.8% 47 12.6%
3 13 16.5% 8 5.5% 4 4.8% 3 4.7% 28 7.5%
4 11 13.9% 4 2.7% 2 2.4% 1 1.6% 18 4.8%
5 17 21.5% 19 13.0% 7 8.3% 4 6.3% 47 12.6%
6 20 25.3% 17 11.6% 7 8.3% 5 7.8% 49 13.1%
7 10 12.7% 18 12.3% 9 10.7% 8 12.5% 45 12.1%
8 17 21.5% 21 14.4% 10 11.9% 7 10.9% 55 14.7%
Midgland
9 20 25.3% 22 15.1% 10 11.9% 8 12.5% 60 16.1%
10 17 21.5% 20 13.7% 4 4.8% 6 9.4% 47 12.6%
11 22 27.8% 19 13.0% 6 7.1% 4 6.3% 51 13.7%
12 17 21.5% 14 9.6% 8 9.5% 4 6.3% 43 11.5%
13 17 21.5% 13 8.9% 5 6.0% 2 3.1% 37 9.9%
14 18 22.8% 18 12.3% 4 4.8% 3 4.7% 43 11.5%
15 13 16.5% 18 12.3% 5 6.0% 5 7.8% 41 11.0%
16 14 17.7% 23 15.8% 9 10.7% 5 7.8% 51 13.7%
17 14 17.7% 18 12.3% 12 14.3% 8 12.5% 52 13.9%
18 15 17.7% 26 17.8% 8 9.5% 8 12.5% 56 15.0%
Apex
19 28 35.4% 34 23.3% 16 19.0% 11 17.2% 89 23.9%
20 23 29.1% 21 14.4% 7 8.3% 4 6.3% 55 14.7%
21 20 25.3% 16 11.0% 7 8.3% 5 7.8% 48 12.9%
22 14 17.7% 14 9.6% 6 7.1% 5 7.8% 39 10.5%
23 14 17.7% 26 17.8% 11 13.1% 3 4.7% 54 14.5%
24 22 27.8% 37 25.3% 20 23.8% 8 12.5% 87 23.3%
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TTMB provides a high rate of cancer detection as initial
biopsy (75.9%) and as repeat biopsy (46.9%). Over half of
all cancers found were Gleason X7; and only a small
minority of cancers were potentially insignificant
(11.1%). The distribution of cancers identified in men
with multiple prior transrectal biopsies suggests that a
template-guided transperineal approach allows better
access to the anterior and apical aspects of the gland, in
which clinically significant prostate cancer is often
located. Increased ability to diagnose apical and anterior
disease has implications for men undergoing active
surveillance, for men who are considering subtotal
prostate gland treatment, for men with initial negative
biopsy but persistently elevated PSA, and for men
considering minimally invasive treatment options.
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